Pharmaceutical composition of benzo nitrogen heteroaromatic ring derivative and use thereof in medicine

MYPI2025005072A0Undetermined Publication Date: 2024-08-22HAISCO PHARMACEUTICAL GROUP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005072
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-22
Filing Date
2024-02-21
Publication Date
2024-08-22

AI Technical Summary

Technical Problem

Existing complement factor B inhibitors have problems such as difficulty in administering therapeutically effective doses, toxic side effects, and ineffective treatment when treating kidney disease, and it is difficult to develop pharmaceutical compositions with good safety, effectiveness, and stability.

Method used

Develop a pharmaceutical composition containing active ingredient A and pharmaceutical excipients. Active ingredient A is selected from specific compounds or derivatives thereof, combined with appropriate pharmaceutical excipients to form a stable, good dissolution, good absorption, and irritating Small, safe pharmaceutical composition for the treatment of kidney disease.

Benefits of technology

The pharmaceutical composition achieves quality stability, good dissolution, good absorption, low irritation, and high safety, improves bioavailability, and can be orally absorbed, significantly improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Abstract PHARMACEUTICAL COMPOSITION OF BENZO NITROGEN HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE A pharmaceutical composition of a benzo nitrogen heteroaromatic ring derivative and the use thereof in medicine. The pharmaceutical composition contains active ingredient A and a pharmaceutical excipient, wherein the active ingredient A is selected from a compound as represented by general formula (I) or a stereoisomer, tautomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof. The pharmaceutical composition contains 1-1000 mg of the active ingredient A, and the content of the active ingredient A is selected from 1.0-90.0%. The present disclosure also relates to the use of the pharmaceutical composition in the preparation of a related drug for treating nephropathy. (I)
Need to check novelty before this filing date? Find Prior Art

Description

A pharmaceutical composition of a benzazepine aromatic ring derivative and its application in medicine Technical Field

[0001] The present invention belongs to the field of pharmaceutical preparations and specifically relates to a pharmaceutical composition comprising a therapeutically effective amount of an active ingredient A and a pharmaceutical excipient. The active ingredient A is selected from a compound of general formula (I) or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof. The pharmaceutical composition comprises 1-1000 mg of the active ingredient A, and the content of the active ingredient A is selected from 1.0% to 90.0%. The present invention also relates to the use of the pharmaceutical composition in preparing a drug for treating kidney disease. Background Art

[0002] Complement factor B is a component of the alternative complement pathway and participates in both specific and nonspecific immune mechanisms. It contains a serine protease (SP) domain that, when activated, provides catalytic activity for the C3 and C5 convertases of the alternative pathway. Complement factor B is a key enzyme in the activation of the alternative complement pathway and serves as a suitable target for inhibiting complement activation.

[0003] Compound 1, described in patent PCT / CN2022 / 113216, exhibits excellent complement factor B inhibitory activity and a high inhibitory rate of C3a levels in vivo. However, when used as a therapeutic agent in humans, administering a therapeutically effective dose is problematic and can lead to toxic side effects or ineffectiveness. Therefore, the development of pharmaceutical compositions or formulations with excellent safety, efficacy, and stability is crucial.

[0004] Summary of the Invention

[0005] The present invention provides a pharmaceutical composition comprising an active ingredient A and a pharmaceutical excipient. The active ingredient A is selected from a compound of formula (I) or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof. The present invention also relates to the use of the pharmaceutical composition in the preparation of a drug for treating kidney disease.

[0006] The pharmaceutical composition of the present invention has stable quality, good dissolution, good absorption, low irritation, good safety, high bioavailability, and can be absorbed orally.

[0007] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of active ingredient A and a pharmaceutical excipient. The pharmaceutical composition can be in the form of a unit preparation.

[0008] The present invention relates to a pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient A and a pharmaceutical excipient, wherein the active ingredient A is selected from the compound of general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals.

[0009] Selected from R 1 Selected from -OCH3 or -OCD3; R 2 Selected from -CH3 or -CD3; n is selected from 1, 2 or 3;

[0010] The content of active ingredient A is selected from 1.0% to 90.0%, preferably from 5.0% to 75.0%, more preferably from 10.0% to 50.0%.

[0011] In some embodiments, the structure of the compound described by formula (I) is selected from one of the structures shown in Table S-1;

[0012] Table S-1 Compound Structure

[0013] In some embodiments, the compound described by general formula (I) is selected from compound 1, whose structure is:

[0014] In some embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is selected from trifluoroacetate or succinate, and further, the molar ratio of compound 1 to succinate is 1:0.75.

[0015] In one aspect, the pharmaceutical composition comprises 1-1000 mg of active ingredient A (calculated as free base);

[0016] In some embodiments, the pharmaceutical composition comprises 5-900 mg of active ingredient A (calculated as free base);

[0017] In some embodiments, the pharmaceutical composition comprises 10-800 mg of active ingredient A (calculated as free base);

[0018] In some embodiments, the pharmaceutical composition comprises 10-400 mg of active ingredient A (calculated as free base);

[0019] In some embodiments, the pharmaceutical composition comprises 20-400 mg of active ingredient A (calculated as free base);

[0020] In some embodiments, the pharmaceutical composition comprises 30-300 mg of active ingredient A (calculated as free base);

[0021] In some embodiments, the pharmaceutical composition comprises 20-200 mg of active ingredient A (calculated as free base);

[0022] In some embodiments, the pharmaceutical composition comprises 30-200 mg of active ingredient A (calculated as free base);

[0023] In some embodiments, the pharmaceutical composition comprises 30-100 mg of active ingredient A (calculated as free base);

[0024] In some embodiments, the pharmaceutical composition comprises 50-100 mg of active ingredient A (calculated as free base);

[0025] In some embodiments, the pharmaceutical composition comprises 5-100 mg of active ingredient A (calculated as free base);

[0026] In some embodiments, the pharmaceutical composition comprises 5 mg of active ingredient A (calculated as free base);

[0027] In some embodiments, the pharmaceutical composition comprises 10 mg of active ingredient A (calculated as free base);

[0028] In some embodiments, the pharmaceutical composition comprises 20 mg of active ingredient A (calculated as free base);

[0029] In some embodiments, the pharmaceutical composition comprises 25 mg of active ingredient A (calculated as free base);

[0030] In some embodiments, the pharmaceutical composition comprises 30 mg of active ingredient A (calculated as free base);

[0031] In some embodiments, the pharmaceutical composition comprises 40 mg of active ingredient A (calculated as free base);

[0032] In some embodiments, the pharmaceutical composition comprises 50 mg of active ingredient A (calculated as free base);

[0033] In some embodiments, the pharmaceutical composition comprises 75 mg of active ingredient A (calculated as free base);

[0034] In some embodiments, the pharmaceutical composition comprises 100 mg of active ingredient A (calculated as free base);

[0035] In some embodiments, the pharmaceutical composition comprises 125 mg of active ingredient A (calculated as free base);

[0036] In some embodiments, the pharmaceutical composition comprises 150 mg of active ingredient A (calculated as free base);

[0037] In some embodiments, the pharmaceutical composition comprises 200 mg of active ingredient A (calculated as free base);

[0038] In some embodiments, the pharmaceutical composition comprises 300 mg of active ingredient A (calculated as free base);

[0039] In some embodiments, the pharmaceutical composition comprises 400 mg of active ingredient A (calculated as free base);

[0040] In some embodiments, the pharmaceutical composition comprises 500 mg of active ingredient A (calculated as free base);

[0041] In some embodiments, the pharmaceutical composition comprises 600 mg of active ingredient A (calculated as free base);

[0042] In some embodiments, the pharmaceutical composition comprises 700 mg of active ingredient A (calculated as free base);

[0043] In some embodiments, the pharmaceutical composition comprises 800 mg of active ingredient A (calculated as free base).

[0044] In another aspect, the content of the active ingredient A in the aforementioned pharmaceutical composition is selected from 1.0%-90.0%, preferably from 5.0%-75.0%, more preferably from 10.0%-50.0%;

[0045] In some embodiments, the active ingredient A in the aforementioned pharmaceutical composition is selected from Compound 1 or its succinate;

[0046] In some embodiments, the active ingredient A in the aforementioned pharmaceutical composition is the succinate salt of Compound 1, preferably, the molar ratio of Compound 1 to succinic acid is 1:0.75;

[0047] In some embodiments, the content of active ingredient A is 1.0%-90.0%; in some embodiments, the content of active ingredient A is 1.0%-80.0%; in some embodiments, the content of active ingredient A is 1.0%-70.0%; in some embodiments, the content of active ingredient A is 1.0%-60.0%; in some embodiments, the content of active ingredient A is 1.0%-50.0%; in some embodiments, the content of active ingredient A is 1.0%-40.0%; in some embodiments, the content of active ingredient A is 1.0% -30.0%; in some embodiments, its content is 1.0%-20.0%; in some embodiments, the content of active ingredient A is 1.0%-10.0%; in some embodiments, the content of active ingredient A is 5.0%-90.0%; in some embodiments, the content of active ingredient A is 5.0%-80.0%; in some embodiments, the content of active ingredient A is 5.0%-70.0%; in some embodiments, the content of active ingredient A is 5.0%-60.0%; in some embodiments, the content of active ingredient A is 5 .0%-50.0%; in some embodiments, the content of active ingredient A is 5.0%-40.0%; in some embodiments, the content of active ingredient A is 5.0%-30.0%; in some embodiments, the content of active ingredient A is 5.0%-20.0%; in some embodiments, the content of active ingredient A is 5.0%-10.0%; in some embodiments, the content of active ingredient A is 10.0%-90.0%; in some embodiments, the content of active ingredient A is 10.0%-80.0%; in some embodiments , the content of active ingredient A is 10.0%-70.0%; in some embodiments, the content of active ingredient A is 10.0%-60.0%; in some embodiments, the content of active ingredient A is 10.0%-50.0%; in some embodiments, the content of active ingredient A is 10.0%-40.0%; in some embodiments, the content of active ingredient A is 10.0%-30.0%; in some embodiments, the content of active ingredient A is 10.0%-20.0%; in some embodiments, the content of active ingredient A is 10.0%.

[0048] In another aspect, the pharmaceutical excipient in the aforementioned pharmaceutical composition is selected from one or more of a filler, a disintegrant, a binder, a glidant, and a lubricant;

[0049] In some embodiments, the filler is selected from one or more of microcrystalline cellulose, mannitol, lactose, sucrose, sorbitol, dextran, pregelatinized starch, monocalcium phosphate, and starch;

[0050] In some embodiments, the filler content is selected from 10.0% to 90.0%, preferably from 20.0% to 80.0%;

[0051] In some embodiments, the filler content is 10.0%-90.0%; in some embodiments, 20.0%-90.0%; in some embodiments, 30.0%-90.0%; in some embodiments, 40.0%-90.0%; in some embodiments, 50.0%-90.0%; in some embodiments, 60.0%-90.0%; in some embodiments, 70.0%-90.0%; in some embodiments, 10.0%-80.0%; in some embodiments, 20.0%-80.0%; in some embodiments, 30.0%-80.0%; in some embodiments, 40.0%-80.0%; in some embodiments, 50.0%-80.0%; in some embodiments, 60.0%-80.0%; in some embodiments, 70.0%-80.0%.

[0052] In some embodiments, the filler is selected from a combination of microcrystalline cellulose and lactose, and its content is selected from 10%-90%, preferably from 20%-80%; wherein the content ratio of microcrystalline cellulose to lactose is 2:1-1:3, preferably from 1:1-1:2;

[0053] In some embodiments, the filler is selected from a combination of microcrystalline cellulose and lactose, and the content ratio of microcrystalline cellulose to lactose is 1:1-1:3; in some embodiments, the content ratio of microcrystalline cellulose to lactose is 1:1-1:2; in some embodiments, the content ratio of microcrystalline cellulose to lactose is 1:1-1:2.5; in some embodiments, the content ratio of microcrystalline cellulose to lactose is 1:1-1:1.5.

[0054] In some embodiments, the filler is selected from a combination of microcrystalline cellulose and lactose, the microcrystalline cellulose content is 15.0%-80.0% of the total content; in some embodiments, the microcrystalline cellulose content is 30.0%-80.0% of the total content; in some embodiments, the microcrystalline cellulose content is 20.0% of the total content; in some embodiments, the lactose content is 30.0%-60.0% of the total content; in some embodiments, the lactose content is 15.0%-60.0% of the total content; in some embodiments, the lactose content is 40.0%-55.0% of the total content.

[0055] In some embodiments, the disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and calcium carboxymethyl cellulose, and its content is selected from 1.0% to 10.0%, preferably from 3.0% to 8.0%;

[0056] In some embodiments, the disintegrant is selected from sodium carboxymethyl starch, and its content is 1.0%-8.0% of the total content; in some embodiments, its content is 3.0%-8.0% of the total content; in some embodiments, its content is 3.0%-5.0% of the total content; in some embodiments, its content is 3.0% of the total content.

[0057] In some embodiments, the binder is selected from one or more of povidone, hydroxypropyl cellulose, hypromellose, and methyl cellulose, and its content is selected from 1.0% to 10.0%, preferably from 2.0% to 8.0%;

[0058] In some embodiments, the binder is selected from copovidone, and its content is 1.0%-8.0% of the total content; in some embodiments, its content is 3.0%-8.0% of the total content; in some embodiments, its content is 3.0%-5.0% of the total content; in some embodiments, its content is 3.0% of the total content.

[0059] In some embodiments, the wetting agent is selected from one or both of water and ethanol.

[0060] In some embodiments, the glidant is selected from one or more of talc, silicon dioxide, micronized silica gel, polyethylene glycol, and magnesium lauryl sulfate, and its content is selected from 0.1% to 3.0%;

[0061] In some embodiments, the glidant is selected from silicon dioxide, and its content is 0.1%-3.0% of the total content; in some embodiments, the content is 0.1%-2.0% of the total content; in some embodiments, the content is 0.1%-1.0% of the total content; in some embodiments, the content is 0.5%-2.0% of the total content; in some embodiments, the content is 0.5%-1.0% of the total content; in some embodiments, the content is 1.0%-3.0% of the total content; in some embodiments, the content is 1.0% of the total content.

[0062] In some embodiments, the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate, and its content is selected from 0.1% to 3.0%;

[0063] In some embodiments, the lubricant is selected from sodium stearyl fumarate, and its content is 0.1%-3.0% of the total content; in some embodiments, the content is 0.1%-2.0% of the total content; in some embodiments, the content is 0.1%-1.0% of the total content; in some embodiments, the content is 0.5%-2.0% of the total content; in some embodiments, the content is 0.5%-1.0% of the total content; in some embodiments, the content is 1.0%-3.0% of the total content; in some embodiments, the content is 1.0% of the total content.

[0064] In some embodiments, the pharmaceutical excipients further comprise one or more of flavoring agents, antioxidants, preservatives, opacifiers, and film coating premixes.

[0065] The pharmaceutical composition according to any embodiment of the present invention comprises the active ingredient A according to any of the preceding embodiments, wherein the active ingredient A is preferably Compound 1 and its succinate salt or a crystalline form thereof, wherein the pharmaceutically acceptable excipient comprises a filler, a disintegrant, and preferably further comprises one or more of a binder, a glidant, a lubricant, and a pH adjuster, including:

[0066] (i) active ingredient A, present in an amount of 1.0% to 90.0%; in some embodiments, 1.0% to 80.0%; in some embodiments, 1.0% to 70.0%; in some embodiments, 1.0% to 60.0%; in some embodiments, 1.0% to 50.0%; in some embodiments, 1.0% to 40.0%; in some embodiments, 1.0% to 30.0%; in some embodiments, 1.0% to 20.0%; in some embodiments, 1.0% to 10.0%; in some embodiments, 5.0% to 90.0%; in some embodiments, 5.0% to 80.0%; in some embodiments, 5.0% to 70.0%; in some embodiments, 5.0% to 60.0%; in some embodiments 5.0%-50.0%; in some embodiments, 5.0%-40.0%; in some embodiments, 5.0%-30.0%; in some embodiments, 5.0%-20.0%; in some embodiments, 5.0%-10.0%; in some embodiments, 10.0%-90.0%; in some embodiments, 10.0%-80.0%; in some embodiments, 10.0%-70.0%; in some embodiments, 10.0%-60.0%; in some embodiments, 10.0%-50.0%; in some embodiments, 10.0%-40.0%; in some embodiments, 10.0%-30.0%; in some embodiments, 10.0%-20.0%; in some embodiments, 10.0%;

[0067] (ii) a filler, wherein the filler is a combination of microcrystalline cellulose and lactose, and the filler content is 50.0%-90.0%, in some embodiments, 60.0%-90.0%; in some embodiments, 70.0%-90.0%; in some embodiments, 50.0%-80.0%; in some embodiments, 60.0%-80.0%; in some embodiments, 70.0%-85.0%; in some embodiments, 75.0%-82.0%; further, in some embodiments, the ratio of microcrystalline cellulose to lactose is 1:1-1:2; in some embodiments, the ratio of microcrystalline cellulose to lactose is 1:1-1:1.5;

[0068] (iii) the disintegrant is cross-linked carboxymethyl cellulose sodium, the content is 1.0%-8.0%; in some embodiments, the content is 1%-3% of the total content; in some embodiments, the content is 3.0%-8.0% of the total content; in some embodiments, the content is 3% of the total content;

[0069] (iv) the binder is copovidone, and the content is 1.0%-8.0%; in some embodiments, the content is 1.0%-3.0% of the total content; in some embodiments, the content is 3.0%-8.0% of the total content; in some embodiments, the content is 3.0% of the total content;

[0070] (v) the lubricant is sodium stearyl fumarate, the content of which is 0.1%-3.0%; in some embodiments, the content is 0.1%-2.0% of the total content; in some embodiments, the content is 0.1%-1.0% of the total content; in some embodiments, the content is 0.5%-2.0% of the total content; in some embodiments, the content is 0.5%-1.0% of the total content; in some embodiments, the content is 1.0%-3.0% of the total content; in some embodiments, the content is 1.0% of the total content;

[0071] (vi) The glidant is silicon dioxide, and the content is 0.1%-3.0%; in some embodiments, the content is 0.1%-2.0% of the total content; in some embodiments, the content is 0.1%-1.0% of the total content; in some embodiments, the content is 0.5%-2.0% of the total content; in some embodiments, the content is 0.5%-1.0% of the total content; in some embodiments, the content is 1.0%-3.0% of the total content; in some embodiments, the content is 1.0% of the total content.

[0072] The pharmaceutical composition according to any embodiment of the present invention, comprising:

[0073] (i) Compound 1 or its succinate salt, in an amount of 1.0% to 90.0%; and optionally,

[0074] (ii) Pharmaceutical excipients include one or more of fillers, binders, wetting agents, disintegrants, glidants, and lubricants.

[0075] (iii) The filler comprises one or more of microcrystalline cellulose, mannitol, lactose, sucrose, sorbitol, dextran, pregelatinized starch, calcium dihydrogen phosphate, and starch.

[0076] (iv) The binder comprises one or more of povidone, hydroxypropyl cellulose, hypromellose, and methyl cellulose.

[0077] (v) The wetting agent comprises one or more of water and ethanol.

[0078] (vi) The disintegrant comprises one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and calcium carboxymethyl cellulose.

[0079] (vii) The glidant comprises one or more of talc, silicon dioxide, micronized silica gel, polyethylene glycol, and magnesium lauryl sulfate.

[0080] (viii) Lubricants include magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate.

[0081] (ix) It may further contain one or more of flavoring agents, antioxidants, preservatives, opacifiers, and film coating premixes.

[0082] Optionally, the pharmaceutical composition described in any of the above schemes can be prepared into a preparation selected from tablets, granules, powders, oral solutions, emulsions or capsules.

[0083] Optionally, in the pharmaceutical preparation described in any of the above schemes, the binder can be added in a solution state or in a powder state; the disintegrant can be added internally, externally, or both internally and externally.

[0084] The present invention also provides use of the pharmaceutical composition in preparing drugs for treating kidney disease.

[0085] Unless otherwise stated, the terms used in this specification and claims have the following meanings.

[0086] "Preparation specifications" refers to the weight of the main drug (active ingredient A) contained in each vial, tablet or other unit preparation.

[0087] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally further replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl, bromine include 79 Br and 81 Br.

[0088] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances where it does not. For example, "alkyl optionally substituted with F" means that the alkyl group may but need not be substituted with F, and the description includes instances where the alkyl group is substituted with F and instances where the alkyl group is not substituted with F.

[0089] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, or the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.

[0090] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.

[0091] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

[0092] "Excipient" refers to an inert substance added to a pharmaceutical composition to facilitate administration of a compound. Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, and disintegrants.

[0093] "Prodrugs" refer to compounds of the present invention that can be converted into biologically active compounds through in vivo metabolism. Prodrugs of the present invention are prepared by modifying amino or carboxyl groups in compounds of the present invention. These modifications can be removed by conventional manipulation or in vivo to yield the parent compound. When the prodrugs of the present invention are administered to a mammalian subject, the prodrugs are cleaved to form free amino or carboxyl groups.

[0094] A "cocrystal" is a crystal formed by the active pharmaceutical ingredient (API) and cocrystal former (CCF) bound together by hydrogen bonds or other non-covalent bonds. Both the API and CCF are solid in their pure form at room temperature, and the components exist in a fixed stoichiometric ratio. A cocrystal is a multi-component crystal, encompassing both binary cocrystals formed between two neutral solids and multi-component cocrystals formed between a neutral solid and a salt or solvate.

[0095] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.

[0096] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, and conformational isomers.

[0097] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomers and amide-imino alcohol isomers.

[0098] “IC 50 "It is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half.

[0099] Unless otherwise specified, the "content %" of a substance in a pharmaceutical composition in this application refers to the percentage of the weight of the substance to the total weight of the pharmaceutical composition.

[0100] The "content %" in the content determination of a preparation refers to the percentage of the weight of the main drug of the preparation obtained by the determination method to the weight of the main drug in the preparation. DETAILED DESCRIPTION

[0101] The following examples illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.

[0102] The compounds used in the reactions described herein were prepared using organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" were obtained from reputable commercial sources, including suppliers such as Titan Technology, Anage Chemical, Shanghai Demo, Chengdu Kelon Chemical, Shaoyuan Chemical Technology, Nanjing Yaoshi, WuXi AppTec, and J&K Technology.

[0103] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker Avance III 400 and Bruker Avance 300 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0104] MS was determined using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0105] HPLC determination was performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM);

[0106] Thin layer chromatography silica gel plate using Yantai Huanghai HSGF 254 or Qingdao GF 254 Silica gel plates, the specifications of silica gel plates used in thin layer chromatography (TLC) are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm;

[0107] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier;

[0108] Boc: tert-butoxycarbonyl;

[0109] Ts: p-toluenesulfonyl;

[0110] Cbz: benzyloxycarbonyl;

[0111] TMS: trimethylsilyl.

[0112] Example 1: Preparation of Compound 1

[0113] first step:

[0114] Compound A (162 mg, 0.625 mmol) was dissolved in 5 mL of isopropyl acetate, and maleic acid (73 mg, 0.628 mmol) was added. The reaction mixture was allowed to react at room temperature for 1 h. The reaction system was concentrated under reduced pressure to obtain a crude product (235 mg). This crude product (235 mg) was dissolved in 10 mL of ethanol, and tert-butyl 4-formyl-5-trideuteromethoxy-7-methyl-1H-indole-1-carboxylate (165 mg, 0.564 mmol) was added. 20 mg of Ir(CO)2acac was added, and the hydrogen atmosphere was replaced three times. The temperature was raised to 80°C, and the mixture was reacted under a hydrogen balloon for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was then purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 10:1) to obtain Compound B (200 mg, yield: 60%).

[0115] LCMS m / z=536.3[M+1] +

[0116] Step 2:

[0117] Compound B (200 mg, 0.37 mmol) was dissolved in 5 mL of methanol, and solid potassium carbonate (257 mg, 1.86 mmol) was added. The mixture was heated to 80°C and refluxed for 3 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was dissolved in a mixture of 5 mL of THF and 1 mL of water, and lithium hydroxide monohydrate (155 mg, 3.7 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction system was concentrated under reduced pressure, and the crude product was subjected to Pre-HPLC (Instrument and Preparative Column: Glison GX-281 Preparative HPLC, Sunfire C18 Preparative Column, 5 μm, ID x Length = 30 mm x 150 mm). Preparation Method: The crude product was dissolved in methanol and dimethyl sulfoxide and filtered through a 0.45 μm filter membrane to prepare a sample solution. The mobile phase system was acetonitrile / water (containing 0.1% TFA). Gradient elution method: acetonitrile was gradient eluted from 5% to 60% (elution time 15 min), and lyophilized to obtain the trifluoroacetic acid salt of compound 1 (125 mg).

[0118] 1H NMR (400MHz, CD3OD) δ8.28-8.18(m,2H),7.77-7.68(m,2H),7.36-7.30(m,1H),6.77( s,1H),6.32(d,1H),4.48(dd,1H),4.40-4.29(m,1H),4.18-4.08(m,1H),3.62-3.52(m ,1H),3.30-3.21(m,1H),2.51(s,3H),2.25-2.12(m,1H),2.09-1.85(m,2H),1.79-1.6 0(m,1H),1.20-1.03(m,1H),0.67-0.53(m,1H),0.52-0.40(m,2H),0.26-0.12(m,2H).

[0119] LCMS m / z=422.2[M+1] +

[0120] To 125 mg of trifluoroacetate of compound 1 were added 10 mL of 2-methyltetrahydrofuran and 50 mL of a saturated sodium bicarbonate solution, stirred for 15 min, extracted, and the organic phase was concentrated to dryness to obtain compound 1 (60 mg).

[0121] Example 1-1: Succinate of Compound 1

[0122] Take about 250 mg of compound 1, add 7.5 mL of ethanol and 2.5 mL of water, stir at 25°C, add 15 mL of 47 mg / mL succinic acid aqueous solution, stir for 2 hours, filter, rinse the filter cake with 30% ethanol aqueous solution, and vacuum dry to obtain the succinate salt of compound 1.

[0123] pass 1 H NMR analysis showed that the H number ratio of the chemical shift methyl peak of compound 1 (2.42 ppm, 3H) to the succinic acid methylene peak (2.41 ppm, 4H) was 1:1, and the molar ratio of compound 1 to succinic acid was preliminarily determined to be 1:0.75.

[0124] Example 2:

[0125] Referring to the preparation method of compound 1, compound 2 or its trifluoroacetate salt is obtained.

[0126] Trifluoroacetate salt of compound 2 1H NMR(400MHz,CD3OD)δ8.23(d,2H),7.73(d,2H),7.33(d,1H),6.77(s,1H),6.33(d,1 H),4.48(dd,1H),4.38-4.31(m,1H),4.17-4.09(m,1H),3.76(s,3H),3.62-3.53(m,1 H),3.30-3.21(m,1H),2.51(s,3H),2.25-2.11(m,1H),2.05-1.88(m,2H),1.78-1.60 (m,1H),1.21-1.05(m,1H),0.65-0.53(m,1H),0.51-0.39(m,2H),0.24-0.14(m,2H).

[0127] LCMS m / z=419.2[M+1] +

[0128] Example 2-1:

[0129] Step 1: Preparation of 5b-1

[0130] 5a (3.7 g, 9.45 mmol) was added to 50 mL of ultra-dry DMF. Benzenesulfonylhydrazide solid (8.2 g, 47.6 mmol) was added under a nitrogen atmosphere, and the temperature was raised to 100°C for 16 h. The reaction solution was cooled to room temperature, and 100 mL of ethyl acetate was added. The organic phase was washed three times with 100 mL of saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was then purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 15:1) to obtain 5b-1 (0.7 g, yield: 19%).

[0131] Rf value of compound 5b-1: 0.36 (developing solvent: ethyl acetate / petroleum ether (v / v) = 1:10)

[0132] Compound 5b-1 NMR:

[0133] 1 H NMR (400MHz, CDCl3) δ8.04-7.90(m,2H),7.50-7.10(m,7H),5.75-5.45(m,1H),5.19(s,2H),4.40-4.05(m,1H),3.85(s, 3H),2.84-2.66(m,1H),2.54-2.33(m,1H),1.84-1.55(m,2H),1.45-1.18(m,1H),0.72-0.27(m,4H),0.09--0.06(m,2H).

[0134] LCMS m / z=394.2[M+1] +

[0135] Step 2: Preparation of the maleate salt of 5c-1

[0136] 5b-1 (1.0 g, 2.54 mmol) was dissolved in 10 mL of acetonitrile, and trimethylsilyl iodide (2.54 g, 12.7 mmol) was slowly added dropwise. The mixture was stirred at room temperature for 30 min. 10 mL of methanol was added to the reaction system, and the pH was adjusted to 2-3 with 2 mol / L dilute hydrochloric acid. The organic phase was extracted with 20 mL of ethyl acetate. The aqueous phase was adjusted to pH 10 with 2 mol / L sodium hydroxide solution, and extracted three times with 100 mL of dichloromethane. The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 5c-1 (diastereomer 2) (0.6 g). Compound 5c-1 (diastereomer 2) (0.6 g, 2.31 mmol) was dissolved in 10 mL of isopropyl acetate, and maleic acid (270 mg, 2.33 mmol) was added. The reaction was allowed to react at room temperature for 16 h. The reaction system was concentrated under reduced pressure to obtain the crude maleate salt of 5c-1 (0.85 g).

[0137] Step 3: Preparation of 5d-1

[0138] The maleate salt of 5c-1 (0.85 g) was dissolved in 10 mL of ethanol, and tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate (0.67 g, 2.32 mmol) (synthesis method, see WO2015009616) was added. Then, 80 mg of Ir(CO)2acac was added. The temperature was raised to 80°C and the mixture was reacted under a hydrogen balloon for 16 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The crude product was then purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 15:1) to afford 5d-1 (850 mg, yield: 69%).

[0139] Compound 5d-1 NMR:

[0140] 1H NMR (400MHz, CDCl3) δ8.08-7.96(m,2H),7.67-7.56(m,2H),7.48(d,1H),6.71(d,1 H),6.67(s,1H),3.91(s,3H),3.80(s,3H),3.74-3.64(m,1H),3.60-3.50(m,1H),3 .44-3.33(m,1H),2.76-2.65(m,1H),2.59(s,3H),2.45-2.32(m,1H),1.96-1.50(m ,13H),1.23-1.10(m,1H),0.90-0.75(m,1H),0.57-0.41(m,2H),0.10-0.01(m,2H).

[0141] LCMS m / z=533.3[M+1] +

[0142] Step 4: Preparation of trifluoroacetate salt of compound 2-1

[0143] Dissolve 5d-1 (850 mg, 1.596 mmol) in 10 mL of methanol, add solid potassium carbonate (1.1 g, 7.96 mmol), and heat to 80°C under reflux for 3 h. Cool the reaction mixture to room temperature and concentrate under reduced pressure to obtain a crude product. Dissolve the crude product in a mixture of 10 mL of THF and 2 mL of water, add lithium hydroxide monohydrate (670 mg, 15.97 mmol), and stir at room temperature for 16 h. Concentrate the reaction mixture under reduced pressure, and the crude product is subjected to Pre-HPLC (instrument and preparative column: Glison GX-281 preparative HPLC, Sunfire C18 preparative column, 5 μm, inner diameter × length = 30 mm × 150 mm). Preparation method: Dissolve the crude product in methanol and dimethyl sulfoxide and filter through a 0.45 μm filter to prepare a sample solution. Mobile phase: acetonitrile / water (containing 0.1% TFA). Gradient elution method: acetonitrile was gradient eluted from 5% to 60% (elution time 15 min), and lyophilized to obtain the trifluoroacetic acid salt of compound 2-1 (400 mg).

[0144] 1H NMR (400MHz, CD3OD) δ8.29-8.18(m,2H),7.79-7.72(m,2H),7.37-7.32(m,1H),6.78( s,1H),6.38(d,1H),4.83-4.78(m,1H),4.41-4.32(m,1H),4.30-4.20(m,1H),3.77(s, 3H),3.65-3.42(m,2H),2.51(s,3H),2.40-2.25(m,1H),2.18-2.02(m,2H),1.98-1.8 2(m,1H),1.52-1.38(m,1H),1.18-1.04(m,1H),0.72-0.60(m,2H),0.25-0.17(m,2H).

[0145] LCMS m / z=419.2[M+1] +

[0146] The trifluoroacetate piperidine ring of compound 5-1 has obvious hydrogen at C1 and C6 of cyclopropyl group. 1 H- 1 The H NOESY signal proves that the configuration of compound 5-1 is as follows:

[0147] Example 3:

[0148] first step:

[0149] 14c (0.40 g, 1.38 mmol), maleate salt of compound A (0.62 g) and Molecular sieves (100 mg) were added to a reaction flask, followed by glacial acetic acid (0.5 mL) and dichloroethane (10 mL). The temperature was raised to 60°C and the reaction mixture was allowed to react for 16 h. The reaction system was cooled to room temperature, and sodium triacetoxyborohydride (0.88 g, 4.15 mmol) was added and allowed to react at room temperature for 6 h. 20 mL of saturated aqueous sodium bicarbonate solution was added dropwise to the reaction system, and the insoluble matter was filtered through a pad of celite. The filtrate was collected and extracted with dichloromethane (20 mL x 3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether (v / v) = 10:1 to 1:0) to obtain crude product 15a (102 mg).

[0150] LCMS m / z=434.3[M+1] +

[0151] Step 2:

[0152] To the crude product 15a (102 mg) was added solid sodium hydroxide (100 mg, 2.50 mmol), followed by the addition of 5 mL of methanol and 5 mL of water. The mixture was heated to 75°C and refluxed for 0.5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was then subjected to pre-HPLC (apparatus and preparative column: SHIMADZU LC-20AP preparative HPLC, Phenomenex C18 preparative column). Preparation method: The crude product was dissolved in methanol and dimethyl sulfoxide and filtered through a 0.45 μm filter to prepare a sample solution. The mobile phase system consisted of acetonitrile / water containing 10 mmol / L ammonium bicarbonate. Gradient elution was performed: 15% to 45% acetonitrile (elution time 10 min). The product was then lyophilized to afford compound 3 (9 mg, two-step yield: 2% based on compound 14c).

[0153] 1 H NMR (400MHz, CD3OD) δ8.16-8.06(m,2H),7.98(s,1H),7.65-7.56(m,2H),7.06(s,1H),4.30-3.83(m,3H),3.79(s,3H),3.40-3.32(m,1H),2.56 (s,3H),2.17-2.03(m,1H),1.99-1.76(m,2H),1.74-1.52(m,1H),1.09 -0.93(m,1H),0.67-0.52(m,1H),0.50-0.36(m,2H),0.23-0.10(m,2H).

[0154] LCMS m / z=420.2[M+1] +

[0155] Example 4:

[0156] 16a (synthesis method, see WO2022028507) (165 mg, 0.868 mmol) was dissolved in 10 mL of dichloromethane, and triethylamine (260.78 mg, 2.6 mmol), (Boc)2O (227.0 mg, 1.04 mmol), and 4-dimethylaminopyridine (5.3 mg, 0.043 mmol) were added sequentially. The reaction was allowed to react at room temperature for 1 h. 50 mL of dichloromethane was added to the reaction solution, and the organic phase was washed sequentially with 0.5 mol / L hydrochloric acid solution (30 mL × 2), water (30 mL × 2), and saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 3:1) to obtain crude product 1 (0.22 g). The crude product 1 (70 mg) was dissolved in 10 mL of 1,2-dichloroethane. Compound A (91 mg), solid sodium bicarbonate (61 mg, 0.726 mmol), and 0.02 mL of acetic acid were added sequentially. After stirring at room temperature for 0.5 h, the mixture was heated to 70°C and allowed to react for 16 h. The reaction mixture was cooled to room temperature, and sodium triacetoxyborohydride (102 mg, 0.48 mmol) was added. The mixture was allowed to react at room temperature for 16 h. 50 mL of saturated aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phase was washed with saturated sodium chloride solution (30 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1:3) to obtain the crude product (40 mg). The crude product was then subjected to pre-HPLC (instrumentation and preparative column: SHIMADZU LC-20AP preparative liquid chromatography, Phenomenex C18 preparative column). Preparation: The crude product was dissolved in methanol and dimethyl sulfoxide and filtered through a 0.45 μm filter to prepare a sample solution. The mobile phase system was acetonitrile / aqueous solution containing 10 mmol / L ammonium bicarbonate. Gradient elution was performed using a gradient elution method: acetonitrile was ramped from 35% to 65% (elution time 10 min) to obtain crude product 2 (8 mg). The crude product 2 (8 mg) was dissolved in a mixture of 2 mL of methanol and 2 mL of water. Solid sodium hydroxide (4 mg, 0.1 mmol) was then added and the mixture was heated to 75°C for 2 h. The reaction solution was cooled to room temperature, adjusted to pH 8 with 1 mol / L aqueous hydrochloric acid, and subjected to pre-HPLC (instrument and preparative column: SHIMADZU LC-20AP preparative HPLC, Phenomenex C18 preparative column). Preparation: The crude product was dissolved in methanol and dimethyl sulfoxide and filtered through a 0.45 μm filter to prepare a sample solution. The mobile phase system was acetonitrile / aqueous solution containing 10 mmol / L ammonium bicarbonate. Gradient elution method: acetonitrile was eluted in a gradient from 35% to 65% (elution time 10 min) to obtain compound 4 (4 mg, yield: 3%).

[0157] 1 H NMR(400MHz,CD3OD)δ8.00(s,1H),7.94-7.84(m,2H),7.48-7.36(m,2H),6. 68(s,1H),4.20-3.70(m,3H),3.59(s,3H),3.23-3.09(m,1H),2.90-2.66(m, 1H),2.38(s,3H),2.00-1.87(m,1H),1.81-1.66(m,2H),1.60-1.40(m,1H), 0.96-0.78(m,1H),0.50-0.35(m,1H),0.34-0.20(m,2H),0.07-0.05(m,2H).

[0158] LCMS m / z=420.3[M+1] +

[0159] Preparation Example:

[0160] Unless otherwise specified, the ratio (%) refers to the percentage of the weight of a component to the total weight of the formulation.

[0161] Unless otherwise specified, the molar ratio of the succinate of compound 1 is 1:0.75.

[0162] 1. Preparation 1-1: Specifications: 200 mg / tablet (calculated as free base):

[0163] Table 2 Preparation prescription (preparation of 300 tablets)

[0164] 2. Preparation 1-2: Specification 200 mg / tablet (calculated as free base):

[0165] Table 3 Preparation prescription (preparation of 300 tablets)

[0166] 3. Preparation 1-3: Specification 200 mg / tablet (calculated as free base): (preparation of 300 tablets)

[0167] Table 4 Preparation prescription

[0168] The above prescription preparations 1-1 to 1-3 adopt the following process:

[0169] 1). Weighing: Weigh the raw and auxiliary materials according to the prescription (converted content of raw materials).

[0170] 2) Mixing: Mix the main drug, binder, glidant, disintegrant and filler for 5 minutes, add lubricant and mix for 2 minutes.

[0171] 3). Tablet pressing: Mix the powders in 2 Use a shallow concave punch to control the tablet weight to 575 mg and the hardness to 70N-130N for tablet compression.

[0172] 4. Preparation 1-4: Specification 200 mg / tablet (calculated as free base):

[0173] Table 5 Preparation prescription (preparation of 300 tablets)

[0174] The formulation process of preparations 1-4 is as follows:

[0175] Premixing: The active ingredient was mixed with microcrystalline cellulose for 1 minute, then sieved using a granulator. After sieving, the mixture was mixed with cross-linked polyvinylpyrrolidone in a wet granulator for 5 minutes to obtain a mixture;

[0176] Adhesive preparation: Prepare 8.7% povidone solution;

[0177] Granulation: Run the wet granulator, slowly add 8.0% povidone solution, and continue stirring for about 120 seconds to make a soft material.

[0178] Granulation drying: Use a swing granulator to pass the soft material through a 14-mesh sieve to obtain wet granules; dry the wet granules in an oven at 80°C to control the moisture content below 3.5%, and use a swing granulator to pass through an 18-mesh sieve to obtain dry granules for later use.

[0179] Total mixing: take the whole and dry granules, place them in a hopper mixer, add magnesium stearate, and mix for 8 minutes to obtain the total mixed granules.

[0180] Tablet compression: Use according to theoretical tablet weight The tablets are pressed using a shallow concave punch, with the tablet weight controlled within ±5% of the theoretical tablet weight and the hardness ranging from 70N to 130N to obtain plain tablets.

[0181] 5. Preparations 1-5: Specifications 50 mg / tablet (based on free base)

[0182] Table 6 Preparation prescription (preparation of 300 tablets)

[0183] 6. Preparations 1-6: Specifications: 100 mg / tablet (based on free base)

[0184] Table 7 Preparation prescription (preparation of 300 tablets)

[0185] 7. Preparations 1-7: Specifications 200 mg / tablet (based on free base)

[0186] Table 8 Preparation prescription (preparation of 300 tablets)

[0187] 8. Preparation 1-8: Specification: 200 mg / tablet (calculated as free base)

[0188] Table 9 Preparation prescription (preparation of 300 tablets)

[0189] 9. Preparation 1-9: Specification 400 mg / tablet (calculated as free base)

[0190] Table 10 Preparation prescription (preparation of 300 tablets)

[0191] 10. Preparation 1-10: Specification 30 mg / tablet (calculated as free base)

[0192] Table 11 Preparation prescription (preparation of 300 tablets)

[0193] 11. Preparation 1-11: Specification: 500 mg / tablet (calculated as free base)

[0194] Table 12 Preparation prescription (preparation of 300 tablets)

[0195] 12. Preparation 1-12: Specification: 700 mg / tablet (calculated as free base)

[0196] Table 13 Preparation prescription (preparation of 300 tablets)

[0197] 13. Preparation 1-13: Specification 800 mg / tablet (calculated as free base)

[0198] Table 14 Preparation prescription (preparation of 300 tablets)

[0199] Prescription preparations 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, and 1-13 were prepared using a similar process to that of prescription preparation 1-4. Purified water was used as a wetting agent during the preparation process.

[0200] Preparation test example:

[0201] 1. Content determination:

[0202] High-performance liquid chromatography (Chinese Pharmacopoeia 2020 edition, Part IV General Rules) test was conducted with octadecylsilane bonded silica gel as the filler (ACE Excel5 C18PFP, 4.6 mm × 250 mm, 5 μm); mobile phase A: 0.02 mol / L ammonium acetate buffer salt-methanol (850:150) (1.54 g of ammonium acetate was weighed, dissolved in 1000 ml of water, filtered through a 0.45 μm filter membrane, and 850 ml was mixed with 150 ml of methanol to obtain the result); mobile phase B: acetonitrile, mobile phase A-mobile phase B = 80:20, and isocratic elution was performed for 30 min; the detection wavelength was 222 nm, the column temperature was 30°C, and the flow rate was 1.0 ml / min.

[0203] The contents of Examples 1-1 to 1-13 above were measured, and the content test results are shown in Table 15 below:

[0204] Table 15 Content determination results

[0205] Conclusion: The contents of the preparations prepared using the technology of the present invention meet the quality requirements.

[0206] 2. Dissolution Determination

[0207] The dissolution rates of the above Examples 1-1 to 1-13 were measured.

[0208] Test method:

[0209] Medium: pH 1.0 dissolution medium; volume: 900 mL; method: paddle method; rotation speed: 50 rpm; time: 30 minutes; temperature: 37°C ± 0.5°C.

[0210] The test results are shown in Table 16 below:

[0211] Table 16 Dissolution determination

[0212] Conclusion: The preparation prepared by the technology of the present invention has good dissolution.

[0213] Biological test cases

[0214] 1. Inhibition test of the alternative complement pathway

[0215] The inhibitory activity of compounds against the alternative complement pathway was assessed using the IBL Alternative Pathway Kit (COMPL AP330RUO). Serum was collected from healthy volunteers and diluted to 50% (v / v) in 20mM EDTA-containing gelatin buffer (0.15mM CaCl2, 141mM NaCl, 4.5mM MgCl2, 4.2mM HEPES, 0.1% gelatin at pH 7.4). Another aliquot was diluted to 50% (v / v) in 20mM EGTA-containing gelatin buffer. Compounds were prepared in DMSO at a 100-fold final concentration. Immediately prior to use, the 50% serum was diluted 1 / 18 with the AP diluent provided in the kit. Ninety-nine aliquots of the diluted EGTA-containing serum were pretreated with one aliquot of compound working solution (v / v) or DMSO (positive control, PC) for 30 minutes. Ninety-nine aliquots of the diluted EDTA-containing serum were pretreated with one aliquot of DMSO (v / v) as a negative control (NC). Serum pretreated with the above compounds (or DMSO) was added to an LPS-coated 96-well plate at 100 mL / well. After incubation at 37°C for 1 hour, the plate was washed three times with the kit's wash buffer. The conjugated chromogenic substrate was added according to the kit's instructions, and the absorbance was read at 405 nm using a microplate reader. The inhibitory activity of the compounds against the alternative pathway was calculated using the following formula.

[0216] OD CPD is the OD value after adding inhibitor, OD NC is the OD value of the negative control, OD PC is the OD value of the positive control.

[0217] The final concentration and inhibition rate of the compound were subjected to nonlinear regression using GraphPad to obtain the IC of the compound for alternative pathway inhibition. 50 .

[0218] ICs that inhibit alternative pathways 50 The results are shown in Table 17.

[0219] Table 17 IC of compounds of the present invention for inhibiting alternative pathways 50 value A: <200nM;

[0220] Conclusion: The compounds of the present invention have a significant inhibitory effect on the alternative complement pathway.

[0221] 2. Pharmacokinetic Test in Rat

[0222] Experimental purpose: This study administered the test substance to SD rats by single-dose intravenous and oral gavage, determined the concentration of the test substance in rat plasma, and evaluated the pharmacokinetic characteristics of the test substance in rats.

[0223] Experimental animals: Male SD rats, 200-250 g, 6-8 weeks old, 6 rats / compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

[0224] Experimental method: On the day of the experiment, 6 SD rats were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.

[0225] Table 18 *Dosage is based on free base.

[0226] Sampling: Before and after drug administration, 0.15 mL of blood was collected from the eye socket under isoflurane anesthesia and placed in an EDTAK2 centrifuge tube. The tube was centrifuged at 5000 rpm and 4°C for 10 min to collect plasma.

[0227] The time points for plasma collection in the IV&PO group were: 0, 5 min, 15 min, 30 min, 1, 2, 4, 6, 8, and 24 h.

[0228] All samples were stored at -60°C before analysis and quantitative analysis was performed using LC-MS / MS.

[0229] Table 19 Pharmacokinetic parameters of the compounds of the present invention in rat plasma Test compounds *Note: Compounds were administered ig (orally)

[0230] Conclusion: The compounds of the present invention have good oral absorption in rats. Compared with LNP023, the trifluoroacetate salt of compound 1 has a higher maximum blood concentration and oral bioavailability in rats.

[0231] Reference compound (LNP023) structure:

[0232] 3. Canine Pharmacokinetic Testing

[0233] Experimental purpose: This study administered the test substance to beagle dogs by single-dose intravenous and oral administration, determined the concentration of the test substance in beagle dog plasma, and evaluated the pharmacokinetic characteristics of the test substance in beagle dogs.

[0234] Test animals: Male beagle dogs, 8-11 kg, 1-3 years old, 6 per compound, purchased from Beijing Masi Biotechnology Co., Ltd.

[0235] Experimental method: On the day of the experiment, 6 beagle dogs were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.

[0236] Table 20 *Dosage is based on the free base.

[0237] Sampling: Before and after administration, collect 1.0 mL of blood from the jugular vein or limb vein and place it in an EDTAK2 centrifuge tube. Centrifuge at 5000 rpm, 4°C for 10 min to collect plasma.

[0238] The time points for plasma collection in the IV&PO group were: 0, 5 min, 15 min, 30 min, 1, 2, 4, 6, 8, 10, 12, and 24 h.

[0239] All samples were stored at -60°C before analysis and quantitative analysis was performed using LC-MS / MS.

[0240] Table 21 Pharmacokinetic parameters of the compounds of the present invention in dog plasma *Note: Compounds were administered ig (orally)

[0241] Conclusion: The compound of the present invention has good oral absorption in beagle dogs.

[0242] 4. Monkey Pharmacokinetic Test

[0243] Purpose: This study administered the test substance to cynomolgus monkeys by single-dose intravenous and oral administration, determined the concentration of the test substance in monkey plasma, and evaluated the pharmacokinetic characteristics of the test substance in monkeys.

[0244] Experimental animals: Male cynomolgus monkeys, 3-5 kg, 3-6 years old, 6 per compound, purchased from Suzhou Xishan Biotechnology Co., Ltd.

[0245] Experimental method: On the day of the experiment, six monkeys were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.

[0246] Table 22 *Dosage is based on the free base.

[0247] Sampling: Before and after administration, 1.0 mL of blood was collected from the limb vein and placed in an EDTAK2 centrifuge tube. Centrifuge at 5000 rpm, 4°C for 10 min to collect plasma.

[0248] The time points for plasma collection in the IV&PO group were: 0, 5 min, 15 min, 30 min, 1, 2, 4, 6, 8, 10, 12, and 24 h.

[0249] All samples were stored at -60°C before analysis and quantitative analysis was performed using LC-MS / MS.

[0250] Table 23 Pharmacokinetic parameters of the compounds of the present invention in monkey plasma *Note: Compounds were administered ig (orally).

[0251] Conclusion: The compounds of the present invention have good oral absorption in monkeys. Compared with the trifluoroacetate salt of LNP023, the trifluoroacetate salt of compound 1 has higher oral exposure and bioavailability in monkeys.

[0252] 5. Caco2 permeability test

[0253] The experiment used Caco-2 cell monolayers in 96-well Transwell plates, incubated in triplicate. Transport buffer (HBSS, 10 mM HEPES, pH 7.4 ± 0.05) containing the compound of the invention (2 μM) or the control compounds digoxin (10 μM), nadolol (2 μM), and metoprolol (2 μM) was added to the apical or basolateral wells of the cell monolayer. Transport buffer containing DMSO was added to the corresponding receiving wells. After incubation at 37 ± 1°C for 2 hours, the cell plate was removed and appropriate samples were taken from the apical and basolateral wells to a new 96-well plate. Proteins were then precipitated by adding acetonitrile containing an internal standard. Samples were analyzed using LC-MS / MS to determine the concentrations of the compound of the invention and the control compound. The concentration data were used to calculate the apparent permeability coefficients for transport from the apical to basolateral side of the cell monolayer and from the basolateral to apical side, thereby calculating the efflux rate. The integrity of the cell monolayer after 2 hours of incubation was assessed by leakage of Lucifer Yellow.

[0254] Table 24 Caco2 test results of the compounds of the present invention

[0255] Conclusion: The compounds of the present invention have good Caco2 permeability. Compared with the trifluoroacetate salt of LNP023, the trifluoroacetate salt of compound 1 has better permeability and lower efflux rate.

Claims

1. A pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient A and a pharmaceutical excipient, wherein the active ingredient A is selected from the compound of general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, Selected from R 1 Selected from -OCH 3 or-OCD 3 ; R 2 Selected from -CH 3 or -CD 3 ; n is selected from 1, 2 or 3; The content of active ingredient A is selected from 1.0% to 90.0%, preferably from 5.0% to 75.0%, more preferably from 10.0% to 50.0%.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises 10-800 mg of active ingredient A (calculated as free base).

3. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition comprises 10-400 mg of active ingredient A (calculated as free base).

4. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises 20-400 mg of active ingredient A (calculated as free base).

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition comprises 30-200 mg of active ingredient A (calculated as free base).

6. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition comprises 30 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg of active ingredient A (calculated as free base).

7. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises an active ingredient A and a pharmaceutical excipient, wherein the active ingredient A is selected from a compound of the general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the structure of the compound of the general formula (I) is selected from one of the structures shown in Table S-1.

8. The pharmaceutical composition according to claim 1, wherein the structure of the compound described in general formula (I) is selected from the following structures:

9. The pharmaceutical composition according to claim 1, wherein the active ingredient A is selected from Compound 1 or a succinate of Compound 1, and preferably, the molar ratio of Compound 1 to succinic acid is 1:0.

75.

10. The pharmaceutical composition according to claim 1, wherein the pharmaceutical excipient is selected from one or more of a filler, a disintegrant, a binder, a glidant, and a lubricant.

11. The pharmaceutical composition according to claim 10, wherein the filler is selected from one or more of microcrystalline cellulose, mannitol, lactose, sucrose, sorbitol, dextran, pregelatinized starch, calcium dihydrogen phosphate, and starch.

12. The pharmaceutical composition according to claim 11, wherein the filler content is selected from 10.0% to 90.0%, preferably from 20.0% to 80.0%.

13. The pharmaceutical composition according to claim 11, wherein the filler is selected from a combination of microcrystalline cellulose and lactose, and its content is selected from 10.0%-90.0%, preferably from 20.0%-80.0%; wherein the content ratio of microcrystalline cellulose to lactose is 2:1-1:3, preferably from 1:1-1:

2.

14. The pharmaceutical composition according to claim 10, wherein the disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and calcium carboxymethyl cellulose, and its content is selected from 1.0%-10.0%, preferably from 3.0%-8.0%.

15. The pharmaceutical composition according to claim 10, wherein the binder is selected from one or more of povidone, hydroxypropyl cellulose, hypromellose, and methyl cellulose, and the content thereof is selected from 1.0% to 10.0%, preferably from 2.0% to 8.0%.

16. The pharmaceutical composition according to claim 10, wherein the wetting agent is selected from one or both of water and ethanol.

17. The pharmaceutical composition according to claim 10, wherein the glidant is selected from one or more of talc, silicon dioxide, micro-powder silica gel, polyethylene glycol, and magnesium dodecyl sulfate, and its content is selected from 0.1%-3.0%.

18. The pharmaceutical composition according to claim 10, wherein the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate, and the content thereof is selected from 0.1% to 3.0%.

19. The pharmaceutical composition according to claim 10, wherein the pharmaceutical excipient further comprises one or more of a flavoring agent, an antioxidant, a preservative, a sunscreen, and a film coating premix.

20. Use of the pharmaceutical composition according to any one of claims 1 to 19 for preparing drugs for treating kidney disease.